The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 21, 2012
Filed:
Oct. 02, 2008
Alessandro Moretta, Genoa, IT;
Mariella Della Chiesa, Genoa, IT;
Pascale Andre, Marseilles, FR;
Laurent Gauthier, Marseilles, FR;
Francois Romagné, La Ciotat, FR;
Peter Andreas Nicolai Reumert Wagtmann, Rungsted Kyst, DK;
Ivan Svendsen, Smørum, DK;
Stefan Zahn, Ballerup, DK;
Anders Svensson, Malmö, SE;
Matthias Thórólfsson, Charlottenlund, DK;
Søren Berg Padkær, Værløse, DK;
Kristian Kjaergaard, Ballerup, DK;
Pieter Spee, Allerød, DK;
Michael Wilken, Hundested, DK;
Alessandro Moretta, Genoa, IT;
Mariella Della Chiesa, Genoa, IT;
Pascale Andre, Marseilles, FR;
Laurent Gauthier, Marseilles, FR;
Francois Romagné, La Ciotat, FR;
Peter Andreas Nicolai Reumert Wagtmann, Rungsted Kyst, DK;
Ivan Svendsen, Smørum, DK;
Stefan Zahn, Ballerup, DK;
Anders Svensson, Malmö, SE;
Matthias Thórólfsson, Charlottenlund, DK;
Søren Berg Padkær, Værløse, DK;
Kristian Kjaergaard, Ballerup, DK;
Pieter Spee, Allerød, DK;
Michael Wilken, Hundested, DK;
University of Genoa, Genoa, IT;
Innate Pharma S.A.S., Marseilles, FR;
Novo Nordisk A/S, Bagsvaerd, DK;
Abstract
Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.